Serological screening, using three different test systems of platelet-transfused patients with hematologic-oncologic disorders.
Sera of hematologic-oncologic patients were tested regularly after platelet transfusions in three test systems: lymphocytotoxicity test, platelet adhesion immunofluorescence test, and--only selected sera--in the monoclonal antibody-specific immobilization of platelet antigen test. Of 388 patients 53 (14%) had HLA antibodies 5 of these in combination with platelet-specific alloantibodies. Lymphocyte-restricted (non-HLA) reactions were observed in 20 patients, the majority of which was attributed to lymphocyte-specific auto- or alloantibodies. Sera of 27 patients showed platelet-specific reactions, usually cold-reacting autoantibodies which have no effect in vivo.
Wernet
D
D
Department of Transfusion Medicine, University of Tübingen, FRG.
Schnaidt
M
M
Mayer
G
G
Northoff
H
H
D000328:Adult; D000906:Antibodies / Q000097:blood; D000918:Antibody Specificity; D001792:Blood Platelets / Q000276:immunology; D002648:Child; D003601:Cytotoxicity Tests, Immunologic; D005455:Fluorescent Antibody Technique; D006680:HLA Antigens / Q000276:immunology; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008403:Mass Screening / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010973:Platelet Adhesiveness / Q000502:physiology; D017713:Platelet Transfusion; D012189:Retrospective Studies; D012698:Serologic Tests
D000906:Antibodies; D006680:HLA Antigens